Skip to main content

Table 2 End of therapy outcomes

From: Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis

Outcome All Patients
(n = 94)
Length of stay, daysa, b 9 [5–17]
Clinical cure, n (%) 80 (85.1)
Mortality, n (%) 5 (5.3)
B. melitensis antibody titera, c 1:320 1:320–1:640
B. melitensis antibody titer < 1:320, n (%)c 28 (29.8)
B. abortus antibody titera, c 1:320 1:160–1:640
B. abortus antibody titer < 1:320, n (%)c 33 (35.1)
Temperature, °Ca 36.7 [36.5–36.9]
white blood cells count, cells/mm3 6.2 ± 3.4
C-reactive protein, mg/La 3.2 [3.1–3.3]
erythrocyte sedimentation rate, mm/hra 8 [5–22]
  1. Data are presented as mean ± SD unless specified otherwise
  2. a Median [IQR]
  3. b Data for hospitalized patients only
  4. c Only 63 of patients had end of therapy serology and hence the percentage reflects this population